Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

[powerpress]

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

[powerpress]

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

[powerpress]

Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.

[powerpress]

The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology.  Here's my discussion of some of the highlights of this work and what this means.

[powerpress]

We've covered a wide range of topics  in our "ASCO 2012 Lung Cancer Highlights" podcast series over the last few weeks.  This webinar and the podcasts from it featured Drs.

We've been producing a series of podcasts from our Lung Cancer Highlights from ASCO 2012 webinar, featuring Drs.